Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-06-21
2011-06-21
Gabel, Gailene R (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S001100, C435S007210, C435S007920, C435S007940, C435S974000, C436S509000, C436S811000
Reexamination Certificate
active
07964360
ABSTRACT:
The invention relates to methods for determining the progression of cartilage degeneration diseases, such as osteoarthritis and rheumatoid arthritis, by quantitating collagen synthesis and degradation markers in patient samples. One can determine whether a cartilage degeneration condition is progressing, regressing, or remaining stable by quantitating collagen synthesis and degradation markers in patient samples and comparing the value obtained to a reference value. When a joint affected by cartilage degeneration in question expresses collagen synthesis and degradation markers, a change in this value is indicative of a change in the progression of the cartilage degeneration condition. The methods and apparatus of the invention allow accurate determination of the therapeutic effects certain cartilage degeneration drug treatments, including osteoarthritis and rheumatoid arthritis drug treatments, so are also useful for pharmaceutical efficacy studies in mammals.
REFERENCES:
patent: RE35306 (1996-07-01), Chen
patent: 5541066 (1996-07-01), Sandell
patent: 5602040 (1997-02-01), May
patent: 5780240 (1998-07-01), Sandell
patent: 5782240 (1998-07-01), Raviv
patent: 5935796 (1999-08-01), Fosang
patent: 6132976 (2000-10-01), Poole et al.
patent: 6352862 (2002-03-01), Davis
patent: 6642007 (2003-11-01), Saltarelli et al.
Sharif et al., A 5-year longitudinal study of Type IIa Collagen Synthesis and total Type II collagen degradation in patient with knee osteoarthritis—association with disease progression, Rheumatology 46 (6): 938-943 (Mar. 26, 2007).
Garnero et al., Uncoupling of Type II Collagen Synthesis and Degradation Predicts Progression of Joint Damage in Patients with Knee Osteoarthritis, Arthritis and Rheumatism 46(10): pp. 2613-2624 (Oct. 2002).
Aigner T, et al., Re-expression of type II A procollagen by adult articular chondrocytes in osteoarthritic cartilage, Arthritis Rheum., 1999, p. 1443-50, vol. 42(7).
Ayral X, et al., Chondroscopy: a new method for scoring chondropathy, Semin. Arthritis Rheum., 1993, p. 289-97, vol. 22(5).
Ayral X, et al., Arthroscopic evaluation of chondropathy in osteoarthritis of the knee, J. Rheumatol., 1996, p. 698-706, vol. 23(4).
Billinghurst RC, et al., Enhanced cleavage of type II collagen by collagenase in osteoarthritic articular cartilage, J. Clin. Invest., 1997, p. 1534-1545, vol. 99.
Campbell CJ, The healing of cartilage defects, Clin. Orthop. Relat. Res., 1969, p. 45-63, vol. 64.
Christgau S, et al., Collagen type II C-telopeptide fragments as an index of cartilage degradation, Bone, 2001, p. 209-15, vol. 29(3).
Conrozier T, et al., Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: A one year prospective study, Ann. Rheum. Dis., 1998, p. 527-32, vol. 57(9).
Dean DD, et al., Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage, J. Clin. Invest., 1989, p. 678-85, vol. 84(2).
Downs JT, et al., Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA, J. Immunol. Methods, 2001, p. 25-34, vol. 247(1-2).
Eastell R, et al., Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption, Osteoporos Int., 1993, p. 255-60, vol. 3(5).
Fife RS, et al., Relationship between arthroscopic evidence of cartilage damage and radiographic evidence of joint space narrowing in early osteoarthritis of the knee, Arthritis Rheum., 1991, p. 377-82, vol. 34(4).
Garnero P, et al., Molecular basis and clinical use of biochemical markers of bone, cartilage and synovium in joint diseases, Arthritis Rheum., 2000, p. 953-61, vol. 43(5).
Garnero P, et al., Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage, Ann. Rheum. Dis., 2001, p. 619-26, vol. 60(6).
Georges C, et al., Serum biologic markers as predictors of disease progression in osteoarthritis of the knee, Arthritis Rheum., 1997, p. 590-1, vol. 40(3).
Hollander AP, et al., Increased damage of type II collagen in osteoarthritic articular cartilage detected by a new immunoassay, J. Clin. Invest., 1994, p. 1722-32, vol. 93(4).
Hollander A.P., et al., Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes and extends into the cartilage with progressive degeneration, J. Clin. Invest, 1995, p. 2859-69, vol. 96(6).
Kim HK, et al., The potential for regeneration of articular cartilage in defects created by chondral shaving and subchondral abrasion: an experimental investigation in rabbits, J. Bone Joint Surgery Am., 1991, p. 1301-15, vol. 73(9).
Lui VC, et al., Tissue-specific and differential expression of alternatively spliced alpha 1 (II) collagen mRNAs in early embryos, Dev. Dyn., 1995, p. 198-211, vol. 203(2).
Moskowitz RW, et al., Abstract, Type II C-telopeptide 2B4 epitope is a marker for cartilage degradation in familial osteoarthritis, Arthritis Rheum., 1998, p. S352, vol. 41 (Suppl).
Nah HD, Type II collagen mRNA containing an alternatively spliced exon predominates in the chick limb prior to chondrogenesis, J. Biol. Chem., 1991, p. 23446-52, vol. 266(34).
Nah HD, et al., Type IIA procollagen: Expression in developing chicken limb cartilage and human osteoarthritic articular cartilage, Dev. Dyn., 2001, p. 307-22, vol. 220(4).
Nelson F, et al., Evidence of altered synthesis of type II collagen in patients with osteoarthritis, J. Clin. Invest., 1998, p. 2115-25, vol. 102(12).
Oganesian A, et al., Type IIA procollagen amino propeptide is localized in human embryonic tissues, J. Histochem. Cytochem., 1997, p. 1469-80, vol. 45(11).
Otterness IG, et al. An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline, Osteoarthritis and Cartilage, 2000, p. 180-5, vol. 8(3).
Poole AR, Cartilage in health and disease. In: Koopman W.J., ed., Arthritis and Allied Conditions: A Textbook of Rheumatology, 1997, Baltimore: Williams & Wilkins, 13 ed., pp. 255-308.
Ravaud P, et al., Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis, Ann. Rheum. Dis., 1998, p. 624-9, vol. 57(10).
Rousseau JC, et al., Abstract, Serum levels of type II A procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis, Arthritis Rheum., 2000, p. S351, vol. 43 (Suppl).
Ryan MC and Sandell LJ, Differential expression of a cysteine-rich domain in the amino-terminal propeptide of type II (cartilage) procollagen by alternative splicing of mRNA, J. Biol. Chem., 1990, p. 10334-9, vol. 265(18).
Sandell LJ, et al., Alternatively spliced type II procollagen mRNAs define distinct populations of cells during vertebral development: differential expression of the amino-propeptide, J. Cell. Biol., 1991, p. 1307-19, vol. 114(6).
Sandell LJ, et al., Alternative splice form of type II procollagen mRNA (IIA) is predominant in skeletal precursors and non-cartilaginous tissues during early mouse development, Dev. Dyn., 1994, p. 129-140, vol. 199(2).
Sharif M, et al., Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee, Arthritis Rheum., 1995, p. 760-7, vol. 38(6).
Sharif M, et al., Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint, Brit. J. Rheumatol., 1995, p. 306-10, vol. 34(4).
Spector TD, et al., Low-levels increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease, Arthritis Rheum., 1997, p. 723-7, vol. 40(4).
Antibodies, A Laboratory Manual, Harlow and Lane, eds., Cold Spring Harbor Laboratory, Ch. 9, (1988).
Altman et al., Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum, 1986, p.
Garnero Patrick
Sandell Linda J.
Barnes-Jewish Hospital
Gabel Gailene R
SNR Denton US LLP
LandOfFree
Uncoupled collagen synthesis and degradation assays does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uncoupled collagen synthesis and degradation assays, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uncoupled collagen synthesis and degradation assays will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2717810